Evolus: Funding, Investors & Team (Sep 2026)

Evolus medical aesthetics company focused on providing physicians and their patients with expanded choices in aesthetic procedures and treatments. They focus on the self-pay aesthetic market and their first product candidate, PrabotulinumtoxinA (DWP-450), is an injectable 900 kDa botulinum toxin type A complex designed to address the needs of the large and growing facial aesthetics market. They believe they will offer physicians and patients a compelling value proposition with DWP-450. Currently, onabotulinumtoxinA (BOTOX) is the neurotoxin market leader and the only known approved 900 kDa botulinum toxin type A complex in the United States. They believe aesthetic physicians generally prefer the performance characteristics of the complete 900 kDa neurotoxin complex and are accustomed to injecting this formulation. We have completed the clinical development program for DWP-450 for the treatment of moderate to severe glabellar lines ("frown lines") between the eyebrows in the US, EU, and Canada. The FDA issued a PDUFA date of May 15, 2018, for completion of its review of our BLA. We submitted an MAA to the EMA and a decision is expected by the second half of 2018. They have also submitted an NDS in Canada. They have an exclusive distribution license to DWP-450 from Daewoong Pharmaceuticals Co.

Evolus has raised $125M across 1 round on record. The most recent is a Post-IPO Debt of $125M announced in Dec 2021.

Evolus' most recent funding round on record is a Post-IPO Debt of $125M, announced in Dec 2021.

David Moatazedi is listed as CEO at Evolus.

Evolus is based in Irvine, California, United States.

Evolus is in the 251-500 employee band.

Evolus' latest round of $125M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.